N/A N=99 Platelet Function in Resuscitated Patients
Acute ST Segment Elevation Myocardial Infarction
Primary: Platelet Inhibition Measured With Optical Aggregometry — 109; 253.8 AU*min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=55 Antiplatelet Therapy in HIV
HIV · Cardiovascular Diseases · Inflammation
Primary: Percentage Platelet Aggregation in PRP After Stimulation With Arachidonic Acid 1600 μM for 5 Min — 72.35; 79.11; 72.79; 26.77 %aggregation
Phase 2 N=40 Effects of Pioglitazone on Platelet Function
Diabetes · Platelet Function · Healthy
Primary: Percent Platelet Aggregation Induced by Arachidonic Acid — 80; 90; 60; 29 maximum percentage aggregation
Phase 1 N=48 Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study
Chronic Kidney Disease
Primary: Whole Blood Platelet Aggregation to 0.5 Millimoles Arachidonic Acid — 21.0; 18.0; 0; 0 ohms
N/A N=334 Platelet Reactivity (High On-Treatment Platelet Reactivity) as Guidance for APT (Antiplatelet Therapy) Adjustment After PCI (Percutaneous Coronary Intervention)
PRU(Platelet Reactivity Unit) · APT(Antiplatelet Therapy) · HOTPR(High on Treat Platelet Reactivity)
Primary: Numbers of Participants With MACE(Major Adverse Cardiac Event) of Study Subjects — 1; 1; 2 numbers of participants with MACE — p=0.002
Phase 4 N=61 Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus
Chronic Kidney Disease (CKD) · Type 2 Diabetes Mellitus (T2DM) · Coronary Artery Disease (CAD)
Primary: Platelet Reactivity Index (PRI) Assessed by VASP. The Cutoff for High Platelet Reactivity is >50% — 67.5; 67.2 PRI%
N/A N=35 Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy
Coronary Artery Disease
Primary: TRAP-induced Platelet Aggregation — 74; 77 percentage of aggregation — p=<0.05
Phase 4 N=24 Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation
Coronary Artery Disease
Primary: Change From Baseline in ADP-mediated Platelet Aggregation, APP, SFFLRN, AYPGKF. — 84; 38; 94; 53 % inhibitn of platelet aggregation — p=0.001
Phase 4 N=5,276 Tailored Antiplatelet Therapy Following PCI
Coronary Artery Disease · Acute Coronary Syndrome · Stenosis
Primary: Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan. — 35; 54 Participants
Phase 2 N=27 Targeting Platelets in Chronic HIV Infection
HIV-1 Infection
Primary: Change in sCD14 From Baseline to Week 24 — 35.75; -251.40; -101.75 pg/mL
Phase 2 N=50 Clopidogrel Pharmacogenomics Project
Disease Susceptibility
Primary: Clopidogrel Resistance, Defined by P2Y12 Reaction Units (PRU)Value >230 — 30; 18 Number of Patients with PRU>230 — p==0.02
Phase 3 N=93 Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events
Stroke · Myocardial Infarctions
Primary: PFA1 — 202.0; 271.1; 234.7 seconds — p=0.0742
N/A N=246 Platelet Activity in Vascular Surgery and Cardiovascular Events
Cardiovascular Disease · Peripheral Artery Disease · Critical Limb Ischemia
Primary: Number of Patients in Which Platelet Activity Measurements Were Associated With Short-term Cardiovascular Events — 31; 16 participants
N/A N=50 Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes
Diabetes Mellitus · Coronary Artery Disease
Primary: P2Y12 Reaction Units — 83; 52 PRU — p=0.022
N/A N=16 PACT (Platelet Activity After Clopidogrel Termination)
Blood Platelets · Clopidogrel
Primary: Change From Baseline in Platelet Surface Activated GPIIb-IIIa Complex at 45 Days After Intervention. — 123.2; 126.7 mean fluorescence intensity (MFI)
Phase 2 N=12 Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease
Blood Platelet Disorders
Primary: Response to Drug Based on Platelet Count at the End of Therapy — 91.6 percentage of participants
N/A N=184 Platelet Inhibition and Bleeding in Patients Undergoing Emergent Cardiac Surgery
Bleeding
Primary: Calculated Blood Loss — 1996 milliters
Phase 4 N=81 Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
Coronary Artery Disease
Primary: Platelet Reactivity Measured as PRU — 154.5; 23; 104 PRU
Phase 1 N=77 Pharmacodynamic Study of Cilostazol in Healthy Volunteers
Healthy
Primary: Ex-vivo Inhibition Of Platelet Aggregation (IPA) — 0.82; 1.21; 1.03; 4.42 ratio
Phase 4 N=20 Reversing Ticagrelor's Effects With Fresh Platelets
Coronary Artery Disease
Primary: P2Y12 Reaction Unit (PRU) — 284.1; 284.1; 39.1; 37.5 PRU
Phase 4 N=82 Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies
Coronary Artery Disease · Peripheral Arterial Disease · Atrial Fibrillation
Primary: Platelet-Mediated Global Thrombogenicity — 66; 59; 69; 71 percentage of aggregation — p=0.275
Phase 4 N=19 Pharmacogenomics of Antiplatelet Response - I
Platelet Aggregation · Platelet Transcriptome · Coronary Artery Disease
Primary: Difference in ADP-induced Platelet Aggregation — -5.2 Difference in ohms (Post-Pre)
Phase 3 N=76 Chronic Kidney Disease (CKD) Platelet Study
Chronic Kidney Diseases · Heart Attack · Stroke, Ischemic
Primary: ADP Induced Platelet Aggregation — 0; 6; 1 ohms — p=0.002
Phase 2 N=15 Anti-Platelets in Chronic Obstructive Pulmonary Disease
COPD · Emphysema · Emphysema or COPD
Primary: Pulmonary Microvascular Blood Volume, CV — 0.89; 0.88; 0.92; 0.91 CV — p=0.84
Phase 4 N=87 P3AMI Antiplatelet Trial
Heart Attack
Primary: Pharmacodynamic Assessment of Degree of Platelet Inhibition as Determined by Verify Now Point of Care Assay and Expressed as P2Y12 Reaction Units (PRU) — 270.23; 247.73…
N/A N=27 The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization
Coronary Artery Disease · Chest Pain
Primary: The Percentage of Coated Platelets After the Administration of Clopidogrel in Patients Undergoing Cardiac Catheterization and/or Angioplasty — 32.8 Percent of platelets…
Phase 4 N=65 A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:
Coronary Artery Disease
Primary: Platelet Reactivity — 36; 33 PRU
Phase 4 N=60 Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction
Myocardial Infarction
Primary: Concentration of Platelet Extracellular Vesicles/ml — 2690000; 4310000 Platelet Extracellular Vesicles/mL
N/A N=20 Effects of Incretins on Human Platelet Function
Inhibition of Platelet Aggregation by Incretins
Primary: Expression of Glucagon Like Peptide -1 (GLP-1) and Gastric Inhibitory Peptide (GIP) Receptors in Normal Human Platelets — 3.73; 4.42 percentage of positive cells — p=0.04
Phase 4 N=30 Platelet Inhibition in Patients With Systolic Heart Failure
Systolic Heart Failure
Primary: The Change in Platelet Aggregation Measured by the Accumetrics (VerifyNow P2Y12) Assay Between Baseline and Each Antiplatelet Medication — 66.4; 156.2 PRU (P2Y12…